<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04706975</url>
  </required_header>
  <id_info>
    <org_study_id>CR845-210601</org_study_id>
    <nct_id>NCT04706975</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica (KOMFORT)</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Adult Subjects With Notalgia Paresthetica</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cara Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cara Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the&#xD;
      efficacy and safety of twice-daily (BID) oral difelikefalin (CR845) in adult subjects with&#xD;
      notalgia paresthetica and moderate to severe pruritus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will consist of a 37-day Screening period, a 7-day Run-In period, a 8-week&#xD;
      Placebo-Controlled Treatment period followed by a 4-week Active Extension period and a Follow&#xD;
      Up visit approximately 14 days after the last dose of study drug.&#xD;
&#xD;
      All subjects will sign an informed consent form (ICF) and undergo screening for study&#xD;
      eligibility.&#xD;
&#xD;
      Subjects will be randomized to receive either placebo or difelikefalin (CR845) tablets at a&#xD;
      dose of 2.0 mg, orally BID. Intake of the first dose of study drug will be at Day 1.&#xD;
&#xD;
      Subjects who complete the Placebo-Controlled Treatment period of the study will transition&#xD;
      into the Active Extension period upon completion of the Week 8 visit assessments. All&#xD;
      subjects in the Active Extension will receive difelikefalin (CR845).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 11, 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the weekly mean of the daily 24-hour Worst Itch-Numeric Rating Scale (WI-NRS) score at Week 8.</measure>
    <time_frame>Baseline, Week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in itch-related quality of life as assessed by the change from baseline to Week 8 in total Skindex-10 Scale score</measure>
    <time_frame>Baseline, Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in itch-related Sleep Disturbance Subscale measured by the Itch Medical Outcomes Study (MOS) at Week 8</measure>
    <time_frame>Baseline, Week 8</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Pruritus</condition>
  <condition>Notalgia Paresthetica</condition>
  <arm_group>
    <arm_group_label>Difelikefalin 2.0 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral difelikefalin 2.0 mg tablet administered twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral placebo tablet administered twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>difelikefalin 2.0 mg</intervention_name>
    <description>Oral difelikefalin 2.0 mg administered twice daily</description>
    <arm_group_label>Difelikefalin 2.0 mg</arm_group_label>
    <other_name>CR845</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral Placebo administered twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
        To be eligible for inclusion into the study, a patient must meet the following criteria:&#xD;
&#xD;
          -  Subject has clinically confirmed diagnosis of active Notalgia Paresthetica;&#xD;
&#xD;
          -  Subject has a history of chronic pruritus due to Notalgia Paresthetica;&#xD;
&#xD;
          -  Subject has moderate to severe pruritus;&#xD;
&#xD;
          -  Female subject is not pregnant or nursing during any period of the study.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
        A patient will be excluded from the study if any of the following criteria are met:&#xD;
&#xD;
          -  Subject has pruritus attributed to a cause other than Notalgia Paresthetica;&#xD;
&#xD;
          -  Subject has any clinically significant medical condition or&#xD;
             physical/laboratory/ECG/vital signs abnormality that would, in the opinion of the&#xD;
             investigator, put the subject at undue risk or interfere with interpretation of study&#xD;
             results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nilam Shah</last_name>
    <role>Study Director</role>
    <affiliation>Cara Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Georgine Ragsdale</last_name>
    <phone>203-406-3700</phone>
    <email>clinicaltrials.gov@caratherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Cromwell</city>
        <state>Connecticut</state>
        <zip>06416</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46250</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Pflugerville</city>
        <state>Texas</state>
        <zip>78660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Markham</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Montr√©al</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Peterborough</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Surrey</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Winnipeg</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 11, 2021</study_first_submitted>
  <study_first_submitted_qc>January 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2021</study_first_posted>
  <last_update_submitted>May 7, 2021</last_update_submitted>
  <last_update_submitted_qc>May 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Notalgia Paresthetica</keyword>
  <keyword>Pruritus</keyword>
  <keyword>CR845</keyword>
  <keyword>Chronic Itch</keyword>
  <keyword>difelikefalin</keyword>
  <keyword>Itch</keyword>
  <keyword>Itching</keyword>
  <keyword>Generalized pruritus</keyword>
  <keyword>NP</keyword>
  <keyword>Neuropathic itch</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pruritus</mesh_term>
    <mesh_term>Back Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

